Data completeness
1/8 — Limited
NORISODRINE (isoproterenol sulfate) by AbbVie is beta-adrenergic agonist with very low affinity for alpha‑adrenergic receptors.
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORISODRINE is an inhaled powder formulation of isoproterenol sulfate, a beta-adrenergic agonist with minimal alpha-adrenergic activity. It is designed for inhalation therapy in respiratory conditions where bronchodilation is indicated. The drug works by stimulating beta-adrenergic receptors to relax airway smooth muscle.
Pre-Launch
Pre-launch stage indicates early commercial team building; small to moderate team size expected during product preparation phase.
Mechanism of Action
beta-adrenergic agonist with very low affinity for alpha‑adrenergic receptors.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NORISODRINE offers entry into a pre-launch pharmaceutical initiative under AbbVie sponsorship, with exposure to regulatory approval, market entry planning, and team buildout. Career growth potential depends on successful regulatory approval and commercial execution post-launch.
Brand ManagerLaunch Manager
Worked on NORISODRINE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.